Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07318597 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

Study acronym: ILLUMINATE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 30 to 32
  2. Trial sites expanded: 27 → 30 locations Eligibility criteria expanded, about 14 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 14 words
  3. Study sites: 25 to 27v9
  4. Study sites: 24 to 25v8
  5. Trial sites expanded: 20 → 24 locationsv7
  6. Trial sites expanded: 11 → 20 locationsv6
  7. Trial sites expanded: 6 → 11 locationsv5
  8. Trial sites expanded: 3 → 6 locations Primary completion date: Mar 8, 2028 to Feb 27, 2028 · Completion date: Sep 27, 2028 to Sep 17, 2028 · Start date changed from estimate of Apr 30, 2026 to May 6, 2026v4 Show 3 more changesShow less
    • Primary completion date: Mar 8, 2028 to Feb 27, 2028
    • Completion date: Sep 27, 2028 to Sep 17, 2028
    • Start date changed from estimate of Apr 30, 2026 to May 6, 2026
  9. Recruitment opened Primary completion pushed from Jan 11, 2028 to Mar 8, 2028 · Completion pushed from Aug 1, 2028 to Sep 27, 2028 · Study sites: 2 to 3 · 1 morev3 Show 4 more changesShow less
    • Primary completion pushed from Jan 11, 2028 to Mar 8, 2028
    • Completion pushed from Aug 1, 2028 to Sep 27, 2028
    • Study sites: 2 to 3
    • Study title shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  10. Trial status: Not Yet Recruiting to Recruiting Start date: Jan 29, 2026 to Apr 30, 2026 · Study sites: 0 to 2 · Primary completion date: Jan 11, 2028 to Mar 8, 2028 · 1 morev2 Show 4 more changesShow less
    • Start date: Jan 29, 2026 to Apr 30, 2026
    • Study sites: 0 to 2
    • Primary completion date: Jan 11, 2028 to Mar 8, 2028
    • Completion date: Aug 1, 2028 to Sep 27, 2028
  11. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Regeneron
151 trials monitored
See 16 trials at risk
Hypertension
1,795 trials monitored
See 85 trials at risk
This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH). The aim of the study is to see how safe and effective REGN13335 is in participants with PAH who are taking other PAH medicines. The study is looking at several other research questions, including: * What side effects may happen from taking REGN13335 * How much REGN13335 is in the blood at different times * Whether the body makes antibodies against REGN13335 (which could make REGN13335 less effective or could lead to side effects)
Trial Details
NCT Number NCT07318597
Lead Sponsor Regeneron Pharmaceuticals
Conditions Pulmonary Arterial Hypertension (PAH)
Enrollment 99 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov